Uso de suvorexant na prevenção do delirium em pacientes críticos
##plugins.themes.bootstrap3.article.sidebar##
Publicado
Jul 27, 2024
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Analisar a efetividade da utilização do suvorexante na prevenção do delirium em pacientes críticos. Métodos: Trata-se de uma revisão integrativa realizado a partir da busca de artigos publicados nos últimos 10 anos nas principais bases de dados eletrônicas, PUBMED, SCIELO e Web of Science. Resultados: A busca resultou em seis trabalhos que convergiram para a efetividade do uso do suvorexante na prevenção do delirium em pacientes gravemente enfermos. Nenhum efeito adverso foi encontrado. Observou uma variação 15 a 20 mg na dose administrada de suvorexante para a prevenção do delirium. Os principais fatores de risco para o delirium relacionados a pacientes na Unidade de Terapia Intensiva (UTI) foram: maior idade, maior score de fragilidade, menor Índice de Massa Corporal, maior demência, maior escore de APACHE II, aumento do uso de ventilador e distúrbios do sono. Foram encontrados também a associação da utilização de suvorexante com a utilização de ventilação mecânica, mortalidade, coadministração de fármacos, como a trazodona. Considerações finais: O suvorexante pode ser bastante efetivo para o tratamento do delirium em pacientes gravemente enfermos, principalmente, ao considerar os leves ou ausentes efeitos adversos comparados àqueles apresentados pelos antipsicóticos amplamente utilizados para o controle do delirium.
##plugins.themes.bootstrap3.article.details##
Como Citar
VianaF., CastroG., & RicardoH. J. W. B. (2024). Uso de suvorexant na prevenção do delirium em pacientes críticos. Revista Eletrônica Acervo Saúde, 24(7), e17805. https://doi.org/10.25248/reas.e17805.2024
Seção
Revisão Bibliográfica
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
1. ANTONIO CH, et al. Delirium em idosos internados: avaliação dos fatores precipitantes. Ciência, Cuidado e Saúde, 2023; 22.
2. ASAI Y, et al. Effect of pharmacist-led intervention protocol on preventing postoperative delirium after elective cardiovascular surgery. PLoS One, 2023; 18(10): e0292786.
3. AZIMARAGHI O, et al. Study protocol for a randomised controlled trial evaluating the effects of the orexin receptor antagonist suvorexant on sleep architecture and delirium in the intensive care unit. BMJ Open, 2020; 10(7): e038474.
4. AZUMA K, et al. Ability of suvorexant to prevent delirium in patients in the intensive care unit: a randomized controlled trial. Acute medicine & surgery, 2018; 5(4): 362-368.
5. BEAUCAGE-CHARRON J, et al. Melatonin and Ramelteon for the treatment of delirium: A systematic review and meta-analysis. Journal of Psychosomatic Research, 2023; 170: 111345.
6. BERGERON N, et al. Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med., 2001; 27(5): 859-64.
7. BOUNDS CG e PATEL, P. Benzodiazepines. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2024; 1.
8. DE LA CRUZ M, et al. The frequency of missed delirium in patients referred to palliative care in a comprehensive cancer center. Support Care Cancer, 2015; 23: 2427-2433.
9. DE MORAES JUNIOR RF, et al. Principais fatores de risco para delirium encontrados nos pacientes idosos internados nas enfermarias de clínica médica de um hospital da Amazônia. Revista Eletrônica Acervo Saúde, 2019; 17: e272.
10. FARASAT S, et al. Sleep and Delirium in Older Adults. Curr Sleep Med Rep., 2020; 6(3): 136-148.
11. HATTA K, et al. Preventive effects of suvorexant on delirium: a randomized placebo-controlled trial. The Journal of clinical psychiatry, 2017; 78(8): 15559.
12. HATTA K, et al. Real-world effectiveness of ramelteon and suvorexant for delirium prevention in 948 patients with delirium risk factors. The Journal of Clinical Psychiatry, 2019; 81(1): 16601.
13. HSHIEH TT, et al. Delirium in the Elderly. Clinics in Geriatric Medicine, 2020; 36(2): 183-199.
14. IKEUCHI S, et al. Efficacy of combined use of Suvorexant and Ramelteon in preventing postoperative delirium: a retrospective comparative study. Journal of Pharmaceutical Health Care and Sciences, 2023; 9(1): 42.
15. IZUHARA M, et al. Real-World Preventive Effects of Suvorexant in Intensive Care Delirium: A Retrospective Cohort Study. Journal of Clinical Psychiatry, 2020; 81(6): 20m13362.
16. IGLSEDER B, et al. Delirium in geriatric patients.Wiener Medizinische Wochenschrift, 2022; 172(5-6): 114-121.
17. KAWADA K, et al. Addition of Suvorexant to Ramelteon Therapy for Improved Sleep Quality with Reduced Delirium Risk in Acute Stroke Patients. Journal of Stroke and Cerebrovascular Diseases, 2019; 28: 142-148.
18. KAWANO S, et al. Trazodone and Mianserin for Delirium: A Retrospective Chart Review. J Clin Psychopharmacol., 2022; 42(6): 560-564.
19. LAWSON TN, et al. A Scoping Review of the Incidence, Predictors, and Outcomes of Delirium Among Critically Ill Stroke Patients. Journal of Neuroscience Nursing, 2022; 54(3): 116-123.
20. LOBO-VALBUENA B, et al. Risk factors associated with the development of delirium in general ICU patients. A prospective observational study. PLoS One, 2021; 16(9): e0255522.
21. LIMA BR, et al. Incidência de delirium após internação de idosos com fraturas: fatores de risco e mortalidade. Revista da Escola de Enfermagem da USP, 2021; 55: e20200467.
22. LUETZ A, et al. Innovative ICU Solutions to Prevent and Reduce Delirium and Post-Intensive Care Unit Syndrome. Semin Respir Crit Care Med., 2019; 40(5): 673-686.
23. MART MF, et al. Prevention and Management of Delirium in the Intensive Care Unit. Seminars in Respiratory and Critical Care Medicine, 2021; 42(1): 112-126.
24. MASUYAMA T, et al. Suvorexant is associated with a low incidence of delirium in critically ill patients: a retrospective cohort study. Psychogeriatrics, 2018; 18(3): 209-215.
25. MATSUOKA A, et al. Evaluation of the delirium preventive effect of dual orexin receptor antagonist (DORA) in critically ill adult patients requiring ventilation with tracheal intubation at an advanced emergency center: A single-center, retrospective, observational study. General Hospital Psychiatry. 2023; 1.
26. MATSUOKA A, et al. Evaluation of suvorexant and lemborexant for the prevention of delirium in adult critically ill patients at an advanced critical care center: a single-center, retrospective, observational study. The Journal of Clinical Psychiatry, 2022; 84(1): 43720.
27. MATTISON MLP. Delirium. Annals of Internal Medicine, 2020; 173(7): ITC49-ITC64.
28. METELLI S e CHAIMANI A. Challenges in meta-analyses with observational studies. Evid Based Ment Health, 2020; 23(2): 83-87.
29. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES (US). LiverTox: clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Disponível em: https://www.ncbi.nlm.nih.gov/books/NBK547900/ Acessado em: 5 de março de 2024.
30. OHSAKO N, et al. Pharmacotherapy for elderly patients with delirium in a general ward setting: A retrospective study. Asian Journal of Psychiatry, 2022; 70: 103024.
31. OKINO K, et al. Use of Suvorexant and Antipsychotics in the Treatment of Delirium After Infectious Diseases: A Retrospective Study. Journal of Clinical Psychopharmacology, 2021; 41(5): 589-593.
32. RAHIMIBASHAR F, et al. Risk factors, time to onset and recurrence of delirium in a mixed medical-surgical ICU population: A secondary analysis using Cox and CHAID decision tree modeling. EXCLI JOURNAL, 2022; 21: 30-46.
33. SHIOTSUKA J, et al. Reducing the effect of immortal time bias affects the analysis of prevention of delirium by suvorexant in critically ill patients: A retrospective cohort study. PLoS One, 2022; 1.
34. STOLLINGS JL, et al. Delirium in critical illness: clinical manifestations, outcomes, and management. Intensive Care Medicine, 2021; 1.
35. TACHIBANA M, et al. Significant decrease in delirium referrals after changing hypnotic from benzodiazepine to suvorexant. Psychogeriatrics, 2021; 21(3): 324-332.
36. TAMURA K, et al. Preventive Effect of Suvorexant for Postoperative Delirium after Coronary Artery Bypass Grafting. Annals of Thoracic and Cardiovascular Surgery, 2019; 25(1): 26-31.
37. VAN DEN BOOGAARD M, et al. Development and validation of PRE-DELIRIC (PREdiction of DELIRium in ICu patients) delirium prediction model for intensive care patients: observational multicentre study. BMJ, 2012; 344: e420.
38. XU S, et al. Suvorexant for the prevention of delirium: A meta-analysis. Medicine, 2020; 99(30): e21043.
39. ZHONG B. How to calculate sample size in randomized controlled trial? Journal of Thoracic Disease, 2009; 1(1): 51-4.
40. WASS S, et al. Delirium in the elderly: a review. Oman Medical Journal, 2008; 23(3): 150-7.
2. ASAI Y, et al. Effect of pharmacist-led intervention protocol on preventing postoperative delirium after elective cardiovascular surgery. PLoS One, 2023; 18(10): e0292786.
3. AZIMARAGHI O, et al. Study protocol for a randomised controlled trial evaluating the effects of the orexin receptor antagonist suvorexant on sleep architecture and delirium in the intensive care unit. BMJ Open, 2020; 10(7): e038474.
4. AZUMA K, et al. Ability of suvorexant to prevent delirium in patients in the intensive care unit: a randomized controlled trial. Acute medicine & surgery, 2018; 5(4): 362-368.
5. BEAUCAGE-CHARRON J, et al. Melatonin and Ramelteon for the treatment of delirium: A systematic review and meta-analysis. Journal of Psychosomatic Research, 2023; 170: 111345.
6. BERGERON N, et al. Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med., 2001; 27(5): 859-64.
7. BOUNDS CG e PATEL, P. Benzodiazepines. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2024; 1.
8. DE LA CRUZ M, et al. The frequency of missed delirium in patients referred to palliative care in a comprehensive cancer center. Support Care Cancer, 2015; 23: 2427-2433.
9. DE MORAES JUNIOR RF, et al. Principais fatores de risco para delirium encontrados nos pacientes idosos internados nas enfermarias de clínica médica de um hospital da Amazônia. Revista Eletrônica Acervo Saúde, 2019; 17: e272.
10. FARASAT S, et al. Sleep and Delirium in Older Adults. Curr Sleep Med Rep., 2020; 6(3): 136-148.
11. HATTA K, et al. Preventive effects of suvorexant on delirium: a randomized placebo-controlled trial. The Journal of clinical psychiatry, 2017; 78(8): 15559.
12. HATTA K, et al. Real-world effectiveness of ramelteon and suvorexant for delirium prevention in 948 patients with delirium risk factors. The Journal of Clinical Psychiatry, 2019; 81(1): 16601.
13. HSHIEH TT, et al. Delirium in the Elderly. Clinics in Geriatric Medicine, 2020; 36(2): 183-199.
14. IKEUCHI S, et al. Efficacy of combined use of Suvorexant and Ramelteon in preventing postoperative delirium: a retrospective comparative study. Journal of Pharmaceutical Health Care and Sciences, 2023; 9(1): 42.
15. IZUHARA M, et al. Real-World Preventive Effects of Suvorexant in Intensive Care Delirium: A Retrospective Cohort Study. Journal of Clinical Psychiatry, 2020; 81(6): 20m13362.
16. IGLSEDER B, et al. Delirium in geriatric patients.Wiener Medizinische Wochenschrift, 2022; 172(5-6): 114-121.
17. KAWADA K, et al. Addition of Suvorexant to Ramelteon Therapy for Improved Sleep Quality with Reduced Delirium Risk in Acute Stroke Patients. Journal of Stroke and Cerebrovascular Diseases, 2019; 28: 142-148.
18. KAWANO S, et al. Trazodone and Mianserin for Delirium: A Retrospective Chart Review. J Clin Psychopharmacol., 2022; 42(6): 560-564.
19. LAWSON TN, et al. A Scoping Review of the Incidence, Predictors, and Outcomes of Delirium Among Critically Ill Stroke Patients. Journal of Neuroscience Nursing, 2022; 54(3): 116-123.
20. LOBO-VALBUENA B, et al. Risk factors associated with the development of delirium in general ICU patients. A prospective observational study. PLoS One, 2021; 16(9): e0255522.
21. LIMA BR, et al. Incidência de delirium após internação de idosos com fraturas: fatores de risco e mortalidade. Revista da Escola de Enfermagem da USP, 2021; 55: e20200467.
22. LUETZ A, et al. Innovative ICU Solutions to Prevent and Reduce Delirium and Post-Intensive Care Unit Syndrome. Semin Respir Crit Care Med., 2019; 40(5): 673-686.
23. MART MF, et al. Prevention and Management of Delirium in the Intensive Care Unit. Seminars in Respiratory and Critical Care Medicine, 2021; 42(1): 112-126.
24. MASUYAMA T, et al. Suvorexant is associated with a low incidence of delirium in critically ill patients: a retrospective cohort study. Psychogeriatrics, 2018; 18(3): 209-215.
25. MATSUOKA A, et al. Evaluation of the delirium preventive effect of dual orexin receptor antagonist (DORA) in critically ill adult patients requiring ventilation with tracheal intubation at an advanced emergency center: A single-center, retrospective, observational study. General Hospital Psychiatry. 2023; 1.
26. MATSUOKA A, et al. Evaluation of suvorexant and lemborexant for the prevention of delirium in adult critically ill patients at an advanced critical care center: a single-center, retrospective, observational study. The Journal of Clinical Psychiatry, 2022; 84(1): 43720.
27. MATTISON MLP. Delirium. Annals of Internal Medicine, 2020; 173(7): ITC49-ITC64.
28. METELLI S e CHAIMANI A. Challenges in meta-analyses with observational studies. Evid Based Ment Health, 2020; 23(2): 83-87.
29. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES (US). LiverTox: clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Disponível em: https://www.ncbi.nlm.nih.gov/books/NBK547900/ Acessado em: 5 de março de 2024.
30. OHSAKO N, et al. Pharmacotherapy for elderly patients with delirium in a general ward setting: A retrospective study. Asian Journal of Psychiatry, 2022; 70: 103024.
31. OKINO K, et al. Use of Suvorexant and Antipsychotics in the Treatment of Delirium After Infectious Diseases: A Retrospective Study. Journal of Clinical Psychopharmacology, 2021; 41(5): 589-593.
32. RAHIMIBASHAR F, et al. Risk factors, time to onset and recurrence of delirium in a mixed medical-surgical ICU population: A secondary analysis using Cox and CHAID decision tree modeling. EXCLI JOURNAL, 2022; 21: 30-46.
33. SHIOTSUKA J, et al. Reducing the effect of immortal time bias affects the analysis of prevention of delirium by suvorexant in critically ill patients: A retrospective cohort study. PLoS One, 2022; 1.
34. STOLLINGS JL, et al. Delirium in critical illness: clinical manifestations, outcomes, and management. Intensive Care Medicine, 2021; 1.
35. TACHIBANA M, et al. Significant decrease in delirium referrals after changing hypnotic from benzodiazepine to suvorexant. Psychogeriatrics, 2021; 21(3): 324-332.
36. TAMURA K, et al. Preventive Effect of Suvorexant for Postoperative Delirium after Coronary Artery Bypass Grafting. Annals of Thoracic and Cardiovascular Surgery, 2019; 25(1): 26-31.
37. VAN DEN BOOGAARD M, et al. Development and validation of PRE-DELIRIC (PREdiction of DELIRium in ICu patients) delirium prediction model for intensive care patients: observational multicentre study. BMJ, 2012; 344: e420.
38. XU S, et al. Suvorexant for the prevention of delirium: A meta-analysis. Medicine, 2020; 99(30): e21043.
39. ZHONG B. How to calculate sample size in randomized controlled trial? Journal of Thoracic Disease, 2009; 1(1): 51-4.
40. WASS S, et al. Delirium in the elderly: a review. Oman Medical Journal, 2008; 23(3): 150-7.